| Withdrawn | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC NCT06592664 | Lisata Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in NCT07500259 | Luxembourg Institute of Health | — |
| Recruiting | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Ad NCT07491445 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642 | Avacta Life Sciences Ltd | Phase 1 |
| Not Yet Recruiting | A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Tre NCT07336953 | West China Hospital | Phase 3 |
| Recruiting | A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer NCT07049055 | Engeneic Pty Limited | Phase 1 / Phase 2 |
| Recruiting | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) NCT07252232 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2) NCT07243262 | Imperial College London | — |
| Recruiting | Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Ap NCT07262957 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 4 |
| Not Yet Recruiting | PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for NCT07047807 | Massachusetts General Hospital | N/A |
| Recruiting | Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer NCT07117045 | Changhai Hospital | — |
| Not Yet Recruiting | PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatm NCT07028424 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Recruiting | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients NCT06922591 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Recruiting | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569 | Alterome Therapeutics, Inc. | Phase 1 |
| Recruiting | Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB) NCT06666803 | IHU Strasbourg | N/A |
| Active Not Recruiting | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Aden NCT06625320 | Revolution Medicines, Inc. | Phase 3 |
| Completed | Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer NCT06947382 | Immunovia, Inc. | — |
| Completed | Early Detection of PDAC in Patients With Chronic Pancreatitis NCT07104864 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Completed | Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting NCT07224802 | City of Hope Medical Center | — |
| Recruiting | Monitoring and Managing Glucose Levels in People With Pancreatic Cancer NCT05132244 | British Columbia Cancer Agency | N/A |
| Recruiting | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals NCT06122896 | Dana-Farber Cancer Institute | EARLY_Phase 1 |
| Unknown | Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients NCT05947825 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resect NCT05853198 | Azienda Ospedaliera Universitaria Integrata Verona | N/A |
| Recruiting | Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma NCT05727020 | Imperial College London | — |
| Recruiting | Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer NCT05845801 | Azienda Ospedaliera Universitaria Integrata Verona | — |
| Active Not Recruiting | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) NCT05642962 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Suspended | Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) NCT04700488 | Cedars-Sinai Medical Center | N/A |
| Completed | Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma NCT05262855 | SOFIE | Phase 2 |
| Recruiting | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer NCT05218889 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | A Prospective Registry for Patients at High-Risk for Pancreatic Cancer NCT06151223 | Mayo Clinic | — |
| Recruiting | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818 | I-Mab Biopharma US Limited | Phase 1 |
| Unknown | Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcino NCT04365049 | Sun Yat-sen University | — |
| Unknown | Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomi NCT05669287 | Radboud University Medical Center | N/A |